



Policy Statement; Prescribing of Debrisoft® wound debridement pad is not supported

Mid Essex Clinical Commissioning Group does not support the prescribing of Debrisoft®.

Debrisoft® is a monofilament debridement pad, it consists of soft, polyester fibres which are secured and knitted together. These fibres are cut at a special angle, length and thickness to ensure good effect and flexibility. Debrisoft® removes wound debris, necrotic material, slough and exudate and long standing hyperkeratotic tissue from surrounding skin.

NICE has developed medical technology guidance MTG17 on the use of Debrisoft® on acute or chronic wounds. NICE medical technologies guidance addresses specific technologies notified to NICE by manufacturers and there is **no requirement** for the NHS to adopt these. The recommendations are based on the **claimed advantages** of introducing the specific technology compared with current management of the condition. The 'case' is reviewed against the evidence submitted and expert advice however the specific recommendations on individual technologies are not intended to limit use of other relevant technologies which may offer similar advantages.

Indications; For the management of acute and chronic wound management including skin ulcers. Also for other skin related conditions such as hyperkeratosis (due to eczema or psoriasis) or dry, scaly/flaky skin which needs to be removed.

Providers commissioned to provide services on behalf of Mid-Essex CCG are reminded that they are required to follow the Mid-Essex CCG formulary and prescribing guidance as detailed in their contract (Medicines Management Service Specification).

See Mid-Essex CCG website – Medicines optimisation page for all prescribing guidance.

<http://midessexccg.nhs.uk/your-health-services/medicines-optimisation>

| | |
|--------------------|---|
| Title | Debrisoft for Wound Debridement |
| Document reference | DebrisoftPOL201502V2.0FINAL |
| Author | Medicines Optimisation Team, Mid Essex CCG |
| Reference: | NICE [MTG17] March 2014 |
| Approved by | Mid Essex Medicines Management Committee Chair: Donald McGeachy |
| Date approved | February 2015 |
| Next review date | February 2020 |

| | |
|------------------|-------------------|
| Previous version | Key Changes |
| May 2014 | Changes to format |